Autolus Therapeutics Net Income vs. Price To Sales
| AUTL Stock | USD 1.44 -0.02 -1.37% |
Net Loss | First Reported 2016-09-30 | Previous Quarter -47.9 M | Current Value -79.1 M | Quarterly Volatility 20.7 M |
Macro event markers
This section tracks how Autolus Therapeutics profitability aligns with revenue trends, asset use, and equity returns.
Trending Equities. Macro event markers
Earnings Share -0.83 | Revenue Per Share | Quarterly Revenue Growth -0.11 | Return On Assets | Return On Equity |
Market capitalization and book value offer complementary views of Autolus Therapeutics - the first driven by investor sentiment, the second by accounting standards. Autolus Therapeutics' market capitalization is 383.25 M. Autolus Therapeutics P/B of 1.44 shows the market assigns a modest premium over accounting equity. Enterprise value stands at 80.34 M. Intrinsic value reflects what Autolus Therapeutics' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
Note that Autolus Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Autolus Therapeutics, key inputs include a P/B ratio of 1.44, ROE of -60.56%, and revenue of 10.12 M. In practice, Autolus Therapeutics price is set by the continuous auction process on its listing exchange.
Autolus Therapeutics Price To Sales vs. Net Income Fundamental Analysis
Peer comparison models estimate Autolus Therapeutics's intrinsic positioning within its sector. Autolus Therapeutics is rated below average for net income within its peer group. It carries a third ranking for price to sales within its peer group . Currently, Net Loss is projected to decrease significantly based on multi-year reporting trends. Year-ago financials show Autolus Therapeutics with Net Loss of -198.6 Million. Comparative earnings metrics contextualize Autolus Therapeutics.Autolus Price To Sales vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Autolus Therapeutics |
| = | -220.66 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Autolus Therapeutics |
| = | 7.50 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Autolus Price To Sales Comparison
Autolus Therapeutics is currently under evaluation for price to sales within its peer group.
Autolus Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Autolus Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Autolus Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Autolus Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Autolus Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -26.3 M | -27.6 M | |
| Operating Income | -217.3 M | -206.4 M | |
| Net Loss | -198.6 M | -188.7 M | |
| Income Before Tax | -197.2 M | -187.4 M | |
| Total Other Income Expense Net | 25.6 M | 27.3 M | |
| Net Loss | -134 M | -127.3 M | |
| Net Loss | -198.6 M | -188.7 M | |
| Income Tax Expense | 1.8 M | 1.8 M | |
| Net Interest Income | 26.5 M | 27.8 M | |
| Interest Income | 37.2 M | 39.1 M | |
| Change To Netincome | 28.9 M | 30.4 M | |
| Net Loss | -0.99 | -1.04 | |
| Income Quality | 0.84 | 0.62 | |
| Net Income Per E B T | 0.91 | 0.76 |
Autolus Profitability Driver Comparison
Profitability drivers for Autolus Therapeutics are the financial and operational factors with the greatest impact on its earnings. Investors must anticipate a wide variety of external disruptions that can affect Autolus Therapeutics' profit margins, market performance, and overall investment attractiveness.
Earnings per Share Projection vs Actual
Use Autolus Therapeutics in pair-trading
Using Autolus Therapeutics in a pair-trading setup can improve risk control because gains and losses are judged against a second position instead of against the market alone. Used properly, pair trading is less about prediction in isolation and more about identifying relative mispricing between related positions.
Autolus Therapeutics Pair Trading
Autolus Therapeutics Pair Trading Analysis
The information in the correlation table below can inform Autolus Therapeutics tax-loss harvesting decisions, showing which instruments historically move in lockstep with Autolus Therapeutics and can serve as viable temporary replacements.
Negative correlation assets provide natural hedges against Autolus Therapeutics positions. When Autolus Therapeutics's value declines, a negatively correlated instrument tends to rise, partially offsetting portfolio losses.
Pair evaluation and Correlation analysis for Autolus Therapeutics provide hedging context. The context can be applied within sectors, industries, or broader universes.Use Investing Themes to Complement your Autolus Therapeutics position
Autolus Therapeutics Healthcare sector classification and 383.25 Million smaller-cap scale make it a natural anchor for themes targeting Biotechnology exposure. Autolus Therapeutics 383.25 Million smaller-cap footprint in Biotechnology aligns sector exposure with portfolio construction goals rather than adding an isolated Healthcare position.
Did You Try This Idea?
Run Investor Favorites Thematic Idea Now
Investor Favorites
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
The Investor Favorites Theme can be deployed as a buy-and-hold allocation or traded actively around individual position volatility.
| View All Next | Launch |
More Resources for Autolus Stock Analysis
Understanding Autolus Therapeutics typically begins with financial statements and long-term trend review. Ratios and trend metrics help frame Autolus Therapeutics' operating context across reporting periods. Key reports that frame Autolus Therapeutics Stock are listed below:Trending Equities. Explore our How to Trade Autolus Stock guide to learn how to trade Autolus Therapeutics effectively.Autolus Therapeutics currently shows ROE of -60.56%, market cap of 383.25 Million. This analysis of Autolus Therapeutics works best as a complementary layer when evaluating how the security fits in a broader portfolio. A thorough Autolus Therapeutics review pairs this page with the quantitative and comparative resources listed below. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Projecting Autolus Therapeutics' profitability starts with historical financial statements. Core statements include the income statement, balance sheet, and cash-flow statement.